

ASGO Webinar #63

"Translating biomarker data into clinical decision in non-dMMR endometrial cancer"

Discussant :
Yutaro Suzuki, MD,
Hokkaido University ,Japan.

August 28, 2025

Biomarker Testing Guidance in Japan

- National guidance recommends **p53 IHC, MMR IHC, and POLE testing** for molecular classification (FIGO 2023).
- Ideally, all patients should be tested according to this framework.

Current Situation in Japan

- **p53 IHC** and **MMR IHC**: reimbursed, but implementation depends on each institution.
- **POLE testing**: not reimbursed by insurance, routine use remains difficult.
- The Japanese Society of Gynecologic Oncology is advocating for insurance coverage of these biomarker tests.

Question:

Should all patients with endometrial cancer undergo biomarker testing according to FIGO 2023 classification?

- Universal testing vs. selective testing in daily practice
- Resource and cost limitations in many Asian settings
- If selective, which biomarkers are most essential?